TACSTD2 and ovarian carcinoma: The results underscored a positive relationship, revealing that higher TACSTD2 expression in ovarian cancer tissues was associated with elevated IC50 values for cisplatin, suggesting TACSTD2 as a predictor of cisplatin treatment response (Figure 4J).